Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures.

Aesthetic surgery journal 2016 Vol.36(4) p. 440-9

Morales R, Ruff E, Patronella C, Mentz H, Newall G, Hustak KL, Fortes P, Bush A

관련 도메인

Abstract

[BACKGROUND] Preventing venous thromboembolism (VTE) remains an important topic in the plastic surgery community. However, there is little consensus regarding appropriate VTE prophylaxis for patients undergoing common body contouring procedures.

[OBJECTIVES] This study compared the use of two novel oral anticoagulants (Rivaroxaban and Apixiban) vs low molecular weight heparin (LMWH) for postoperative chemical prophylaxis in body contouring plastic surgery procedures.

[METHODS] A single center retrospective chart review of 1572 patients who underwent body contouring plastic surgery procedures from January 2012 to February 2015 was performed. Major complications associated with chemical prophylaxis were reviewed including hematomas requiring surgical evacuation, acute blood loss anemia requiring transfusions, and thrombotic or hemorrhagic events.

[RESULTS] Drug-related adverse events occurred in 1.27% (n = 20) of patients. The complications encountered by the 454 patients on LMWH consisted of 0.88% (n = 4) with hematomas requiring surgical evacuation, 0.44% (n = 2) with decreased hemoglobin requiring transfusions, and 0.22% (n = 1) with a deep vein thrombosis (DVT). The complications encountered by 703 patients on with Rivaroxaban consisted of 1.3% (n = 9) with hematomas requiring surgical evacuation, 0.43% (n = 3) with decreased hemoglobin requiring transfusions, and 0.1% (n = 1) with a DVT and pulmonary embolism. The complications encountered by 415 patients on with Apixaban consisted of 0.48% (n = 2) with a DVT.

[CONCLUSIONS] Novel oral anticoagulants (Rivaroxaban and Apixiban) are comparable to LMWH for chemical prophylaxis after body contouring procedures with similar rates of drug-related complications. Further investigation is warranted with more clinical cases in order to recommend the use of this medication for routine postoperative chemical prophylaxis after body contouring procedures.

[LEVEL OF EVIDENCE] 3 Therapeutic.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 liposuction 지방흡입 dict 1
해부 oral anticoagulants scispacy 1
해부 blood scispacy 1
해부 pulmonary scispacy 1
합병증 Oral Anticoagulants scispacy 1
합병증 hematomas scispacy 1
합병증 DVT → deep vein thrombosis scispacy 1
약물 Heparin C0019134
heparin
scispacy 1
약물 Rivaroxaban C1739768
rivaroxaban
scispacy 1
약물 LMWH → low molecular weight heparin C0019139
Heparin, Low-Molecular-Weight
scispacy 1
약물 Apixaban C1831808
apixaban
scispacy 1
약물 Thromboprophylaxis scispacy 1
약물 [BACKGROUND] scispacy 1
약물 [OBJECTIVES] scispacy 1
약물 [RESULTS] Drug-related scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 venous thromboembolism C1861172
Venous Thromboembolism
scispacy 1
질환 VTE → venous thromboembolism C1861172
Venous Thromboembolism
scispacy 1
질환 hematomas C0018944
Hematoma
scispacy 1
질환 blood loss anemia C0154286
Iron deficiency anemia secondary to chronic blood loss
scispacy 1
질환 thrombotic C0087086
Thrombus
scispacy 1
질환 hemorrhagic C0333275
Hemorrhagic
scispacy 1
질환 vein thrombosis C0042487
Venous Thrombosis
scispacy 1
질환 DVT → deep vein thrombosis C0149871
Deep Vein Thrombosis
scispacy 1
질환 pulmonary embolism C0034065
Pulmonary Embolism
scispacy 1
질환 transfusions scispacy 1
기타 Body scispacy 1
기타 venous scispacy 1
기타 patients scispacy 1
기타 hemoglobin scispacy 1
기타 transfusions scispacy 1

MeSH Terms

Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Factor Xa Inhibitors; Female; Hematoma; Heparin, Low-Molecular-Weight; Humans; Lipectomy; Male; Middle Aged; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Texas; Treatment Outcome; Venous Thromboembolism; Young Adult

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문